0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure avoids interest expense, refinancing needs, and lender constraints. This gives ATOS greater flexibility to allocate available capital to clinical development, although it does not eliminate the need for future equity funding.
Fresh Funding For Clinical DevelopmentThe financing provides additional resources to continue clinical programs and fund working capital. Maintaining development activity is essential for a clinical-stage biotech seeking to advance candidates toward potential value-creating milestones.
Focused Breast-cancer Development StrategyConcentration on breast cancer and related diseases can support focused scientific expertise, trial design, and resource allocation. A defined therapeutic focus may help the company build a coherent pipeline rather than spreading limited capital across unrelated areas.
Bears Say
No Commercial RevenueWithout product sales or recurring operating revenue, ATOS has no demonstrated commercial engine to fund research and development. Its ability to create value therefore remains dependent on clinical progress, financing access, or future licensing and partnership income.
Escalating Cash Burn And LossesIncreasing operating cash outflows alongside a TTM net loss of about $37.7 million indicate that the business is not self-funding. Sustained burn raises the probability of additional capital raises and heightens execution risk if financing conditions weaken.
Shrinking Equity Increases Funding RiskThe substantial decline in equity reflects cumulative losses and ongoing cash usage, reducing the company’s financial cushion. Continued funding needs may require further equity issuance, creating dilution risk and limiting resources available for long-term development.
Atossa Therapeutics News
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $25.15M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 69 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in GB:0HJ7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.